Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Non Operating Income (2016 - 2025)

Historic Non Operating Income for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$23337.0.

  • China Pharma Holdings' Non Operating Income rose 2853.25% to -$23337.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $45066.0, marking a year-over-year increase of 12701.39%. This contributed to the annual value of -$147499.0 for FY2024, which is 5489.3% up from last year.
  • Per China Pharma Holdings' latest filing, its Non Operating Income stood at -$23337.0 for Q3 2025, which was up 2853.25% from $123753.0 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Non Operating Income peaked at $123753.0 during Q2 2025, and registered a low of -$332029.0 during Q4 2021.
  • Its 5-year average for Non Operating Income is -$71782.4, with a median of -$64265.0 in 2021.
  • As far as peak fluctuations go, China Pharma Holdings' Non Operating Income crashed by 20876.94% in 2021, and later skyrocketed by 36551.31% in 2025.
  • Over the past 5 years, China Pharma Holdings' Non Operating Income (Quarter) stood at -$332029.0 in 2021, then skyrocketed by 71.34% to -$95172.0 in 2022, then soared by 49.86% to -$47722.0 in 2023, then soared by 40.5% to -$28396.0 in 2024, then increased by 17.82% to -$23337.0 in 2025.
  • Its Non Operating Income was -$23337.0 in Q3 2025, compared to $123753.0 in Q2 2025 and -$26954.0 in Q1 2025.